Zacks Research Has Bullish Estimate for NKTR FY2024 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at Zacks Research upped their FY2024 earnings estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Monday, January 6th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($0.76) per share for the year, up from their prior forecast of ($0.80). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

NKTR has been the subject of a number of other research reports. BTIG Research reaffirmed a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. B. Riley began coverage on shares of Nektar Therapeutics in a research report on Wednesday. They set a “buy” rating and a $4.00 price objective for the company. Piper Sandler started coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective for the company. Finally, HC Wainwright started coverage on shares of Nektar Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $6.50 target price on the stock. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $4.08.

Nektar Therapeutics Trading Down 9.6 %

NASDAQ:NKTR opened at $1.03 on Thursday. Nektar Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.93. The company has a market cap of $189.99 million, a PE ratio of -1.23 and a beta of 0.59. The company has a 50 day simple moving average of $1.09 and a two-hundred day simple moving average of $1.21.

Hedge Funds Weigh In On Nektar Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its stake in Nektar Therapeutics by 2,822.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after acquiring an additional 532,663 shares in the last quarter. Nantahala Capital Management LLC grew its stake in Nektar Therapeutics by 66.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 1,634,046 shares in the last quarter. Samlyn Capital LLC bought a new position in Nektar Therapeutics in the 2nd quarter worth about $11,728,000. Millennium Management LLC grew its stake in Nektar Therapeutics by 56.1% in the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock worth $5,778,000 after acquiring an additional 1,674,924 shares in the last quarter. Finally, Eventide Asset Management LLC grew its stake in Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after acquiring an additional 1,870,904 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now directly owns 351,892 shares in the company, valued at approximately $316,702.80. This represents a 8.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 46,995 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now owns 1,195,710 shares in the company, valued at $1,207,667.10. The trade was a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 155,575 shares of company stock worth $149,878 in the last 90 days. 3.71% of the stock is currently owned by corporate insiders.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.